Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
People›
Jeffrey Leiden
AddedMar 31, 2024
UpdatedJun 28, 2026
Jeffrey Leiden

Jeffrey Leiden

Board Member, Vertex Pharmaceuticals

CrunchbaseLinkedIn

Jeffrey Leiden's Career

Vertex Pharmaceuticals
Vertex Pharmaceuticals

Boston, MA, US

Board Member· Board
Casana
Casana

Rochester, NY, US

Board Member· Board
Odyssey Therapeutics
Odyssey Therapeutics

Cambridge, MA, US

Board Member· Board

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

Jeffrey Leiden's Career

Vertex Pharmaceuticals
Vertex Pharmaceuticals
Public$656.2M4.8k1989Boston, MA, US
Board Member· Board

Leadership at Vertex Pharmaceuticals

Margaret McGlynnMargaret McGlynnBoard Member
H. Daniel PerezH. Daniel PerezBoard Member
Joshua BogerJoshua BogerFounder
Sangeeta BhatiaSangeeta BhatiaBoard Member
Yuchun LeeYuchun LeeBoard Member
Reshma KewalramaniReshma KewalramaniBoard Member

Similar to Vertex Pharmaceuticals

PTC TherapeuticsPTC TherapeuticsSouth Plainfield, NJ, USPharmaceuticalsest. 1998PTC TherapeuticsSouth Plainfield, NJ, US · est. 1998

PTC Therapeutics, Inc.: A US-based pharmaceutical company specializing in oral, small-molecule drugs for genetic disorders, oncology, and infectious diseases.

Public · $1.6B1.4k
SynspiraSynspiraFramingham, MA, USBiotechest. 2017SynspiraFramingham, MA, US · est. 2017

Synspira Therapeutics: A clinical-stage biotech firm innovating treatments for cystic fibrosis and rare diseases.

Series B · $25.2M8
Gilead SciencesGilead SciencesFoster City, CA, USPharmaceuticals, Therapiesest. 1987Gilead SciencesFoster City, CA, US · est. 1987

Gilead Sciences: An American biopharmaceutical firm innovating therapies for critical diseases.

Public · $2B17k
Vertice PharmaVertice PharmaNew Providence, NJ, USHealth, Pharmaceuticalsest. 2015Vertice PharmaNew Providence, NJ, US · est. 2015

Vertice Pharma: A UK-based specialty pharmaceuticals company, developing and distributing quality, affordable health solutions.

Private Equity · $300M175
Casana
Casana
Series B$56.3M842018Rochester, NY, US
Board Member· Board

Leadership at Casana

David BorkholderDavid BorkholderCo-Founder
Khan SiddiquiKhan SiddiquiBoard Member
Austin McChordAustin McChordCEO
Nicholas ConnNicholas ConnCo-Founder
Odyssey Therapeutics
Odyssey Therapeutics
Series C$487M1752021Cambridge, MA, US
Board Member· Board

Leadership at Odyssey Therapeutics

Gary GlickGary GlickBoard Member
Jill CarrollJill CarrollBoard Member
Carl L. GordonCarl L. GordonBoard Member
Valerie OdegardValerie OdegardBoard Member
David L. PomplianoDavid L. PomplianoCo-Founder
Charles Baum, MD, PhDCharles Baum, MD, PhDBoard Member

Similar to Odyssey Therapeutics

Odyssey TheraOdyssey TheraSan Ramon, CA, USCancer Therapiesest. 2000Odyssey TheraSan Ramon, CA, US · est. 2000

Odyssey Thera, Inc.: A US-based biopharmaceutical company specializing in cancer therapies.

Public · $6.3M30
Nested TherapeuticsNested TherapeuticsCambridge, MA, USTherapeuticsest. 2021Nested TherapeuticsCambridge, MA, US · est. 2021

Nested Therapeutics: A biotech innovator designing impactful therapeutics through creative service.

Series A · $125M50
Synnovation TherapeuticsSynnovation TherapeuticsWilmington, DE, USOncology Therapiesest. 2021Synnovation TherapeuticsWilmington, DE, US · est. 2021

Synnovation Therapeutics: Precision oncology firm specializing in small molecule therapies for cancer.

Series A · $139M18
Scorpion TherapeuticsScorpion TherapeuticsBoston, MA, USCancer Treatmentest. 2020Scorpion TherapeuticsBoston, MA, US · est. 2020

Scorpion Therapeutics, a Boston-based medical organization, innovates in precision oncology for enhanced cancer treatment.

Series B · $270M130

Jeffrey Leiden's Co-Investors

Ariel KatzAriel KatzCo-invested · Osmind Series BHelena GoodmanHelena GoodmanCo-invested · Osmind Series BLachy GroomLachy GroomCo-invested · Osmind Series BBrent SaundersBrent SaundersCo-invested · Osmind Series BAlice ZhangAlice ZhangCo-invested · Osmind SeedAdrian AounAdrian AounCo-invested · Osmind Series A

Jeffrey Leiden's Similar Executives & Operators

Lau Eng BoonLau Eng BoonBoard Member · BukalapakJay Geoffrey WacherJay Geoffrey WacherBoard Member · BukalapakSoemantri BrodjonegoroSoemantri BrodjonegoroBoard Member · BukalapakWILL WEI CHENGWILL WEI CHENGBoard Member · DiDiDhirubhai H. AmbaniDhirubhai H. AmbaniBoard Member · Reliance RetailMason YeoMason YeoBoard Member · KakaoJaeHong ChoiJaeHong ChoiBoard Member · KakaoSean JohSean JohBoard Member · Kakao

People Similar to Jeffrey Leiden

Jean-Jacques BienaimeJean-Jacques BienaimeBoard Member · Fox Chase Cancer CenterRichard GonzalezRichard GonzalezBoard Member · AbbVieDavid LoewDavid LoewBoard Member · IpsenGeorge ScangosGeorge ScangosBoard Member · Agilent TechnologiesDave RicksDave RicksBoard Member · Eli Lilly and Company